Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
- Establish and bank cell lines and/or xenografts from pediatric patients with cancer.
- Establish continuous cell lines, under carefully controlled conditions, from pediatric
patients with cancer.
- Establish transplantable xenografts in immunocompromised mice from tumor cells that are
difficult to establish as continuous cell lines in vitro.
- Create a bank of cell lines and generate sufficient vials of cryopreserved cells for
distribution to investigators with approved COG biology protocols.
- Characterize cell lines from childhood cancers with respect to DNA short tandem repeat
molecular profile as a "fingerprint" of original cell line identity.
- Characterize cell lines for the ability for sustained growth in tissue culture and/or
as mouse xenografts.
- Characterize cell lines for mycoplasma contamination.
- Characterize cell lines for expression of molecular makers that confirm the tumor-type
of the cell line and the immortal nature of the cells (telomerase) and the expression
of molecular markers that may correlate with drug resistance.
OUTLINE: This is a multicenter study. Specimens are stratified according to disease (acute
lymphoblastic leukemia vs acute myeloid leukemia vs lymphoma vs osteogenic sarcoma vs Ewing
family of tumors vs rhabdomyosarcoma vs primitive neuroectodermal tumor vs glioma vs
astrocytoma vs rhabdoid tumors vs hepatoblastoma vs retinoblastoma vs Wilms tumor vs germ
cell tumors vs other diagnoses).
Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood
and/or bone marrow are also collected and banked.
Cell lines are established and characterized via reverse-transcriptase polymerase chain
reaction and/or flow cytometry for biomarkers and by DNA fingerprinting.
Markers to be identified may include the following:
- Neuroblastoma: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I,
and HSAN 1.2 antigens
- Ewing family of tumors: EWS-FLI1, EWS-ERG, and PGP 9.5
- Retinoblastoma: interphotoreceptor retinoid-binding protein
- Acute lymphoblastic leukemia: immunophenotype
- Alveolar rhabdomyosarcoma: PAX3-FKHR, PAX7-FKHR, and MyoD1
- All cell types: telomerase expression including hTR and hTERT Mutations of TP53 gene
are detected by flow cytometry and/or immunocytochemistry.
No results of these tests are provided to the patient, the patient's physician, or the
patient's medical records.
PROJECTED ACCRUAL: A total of 500 specimens per stratum will be accrued for this study.
Establishment and banking of cell lines and/or xenografts from pediatric patients with cancer
C. Patrick Reynolds, MD, PhD
Children's Hospital Los Angeles
|Presbyterian - St. Luke's Medical Center||Denver, Colorado 80218|
|Bronson Methodist Hospital||Kalamazoo, Michigan 49007|
|Ellis Fischel Cancer Center at University of Missouri - Columbia||Columbia, Missouri 65203|
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|
|Children's Mercy Hospital||Kansas City, Missouri 64108|
|All Children's Hospital||St. Petersburg, Florida 33701|
|Saint Jude Midwest Affiliate||Peoria, Illinois 61637|
|Driscoll Children's Hospital||Corpus Christi, Texas 78466|
|City of Hope Comprehensive Cancer Center||Duarte, California 91010|
|Southern California Permanente Medical Group||Downey, California 90242|
|Kosair Children's Hospital||Louisville, Kentucky 40202-3830|
|East Tennessee Children's Hospital||Knoxville, Tennessee 37901|
|Covenant Children's Hospital||Lubbock, Texas 79410|
|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences||Little Rock, Arkansas 72205|
|Blumenthal Cancer Center at Carolinas Medical Center||Charlotte, North Carolina 28232-2861|
|Carol G. Simon Cancer Center at Morristown Memorial Hospital||Morristown, New Jersey 07962|
|Jonathan Jaques Children's Cancer Center at Miller Children's Hospital||Long Beach, California 90801|
|Lee Cancer Care of Lee Memorial Health System||Fort Myers, Florida 33901|
|St. Joseph's Cancer Institute at St. Joseph's Hospital||Tampa, Florida 33607|
|Kaplan Cancer Center at St. Mary's Medical Center||West Palm Beach, Florida 33407|
|Ochsner Cancer Institute at Ochsner Clinic Foundation||New Orleans, Louisiana 70121|
|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital||Baltimore, Maryland 21215|
|Hackensack University Medical Center Cancer Center||Hackensack, New Jersey 07601|
|Wake Forest University Comprehensive Cancer Center||Winston-Salem, North Carolina 27157-1096|
|Rainbow Babies and Children's Hospital||Cleveland, Ohio 44106-5000|
|Texas Tech University Health Sciences Center School of Medicine - Amarillo||Amarillo, Texas 79106|
|Methodist Children's Hospital of South Texas||San Antonio, Texas 78229-3993|
|Mountain States Tumor Institute at St. Luke's Regional Medical Center||Boise, Idaho 83712-6297|
|University of Illinois Cancer Center||Chicago, Illinois 60612-7243|
|Simmons Cooper Cancer Institute||Springfield, Illinois 62794-9677|
|Lucille P. Markey Cancer Center at University of Kentucky||Lexington, Kentucky 40536-0093|
|Tulane Cancer Center Office of Clinical Research||Alexandria, Louisiana 71315-3198|
|CCOP - Nevada Cancer Research Foundation||Las Vegas, Nevada 89109-2306|
|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center||New York, New York 10032|
|Akron Children's Hospital||Akron, Ohio 44308-1062|
|Tod Children's Hospital||Youngstown, Ohio 44501|
|Oklahoma University Cancer Institute||Oklahoma City, Oklahoma 73104|
|Children's Hospital of Pittsburgh of UPMC||Pittsburgh, Pennsylvania 15213|
|Madigan Army Medical Center - Tacoma||Tacoma, Washington 98431|
|Connecticut Children's Medical Center||Hartford, Connecticut 06106|
|BI-LO Charities Children's Cancer Center||Greenville, South Carolina 29605|
|Children's Hospital of Alabama at University of Alabama at Birmingham||Birmingham, Alabama 35233|